An Acridinium Ester for Determination of Serum Arylesterase Activity in Patients with Coronary Heart Disease

Abstract:

Paraoxonase (PON) is a hydrolyase correlated with many chronic diseases. The use of 9-(4-chlorophenyloxycarbonyl)-10-methylacridinium triflate ester (CPOCMA) as a substrate for determination of serum arylesterase PON activity had been reported. It is meaningful to compare this substrate with phenyl acetate further with serum samples of patients with coronary heart disease (CHD, n=104). Correlations of PON arylesterase activity with CHD and also with age were analyzed. There was no significant difference in serum arylesterase activity (based on the CPOCMA or the phenyl acetate) between of the CHD inpatients and controls at same age level (45-60 years old). Statistically negative correlation of serum PON CPOCMAase activity (p=0.020) but not the activity based on phenyl acetate (p>0.05) with age was observed. Based on the both substrates, significant decrease in PON activity was found in the old CHD inpatients (≥60 years old), compared with that in the young CHD inpatients (<60 years old), or with that in the young controls. The methods based on CPOCMA substrate and based on the phenyl acetate demonstrated consistent results in correlation with CHD, but different results in correlation of PON activity with age.

• Periodical: Advanced Materials Research (Volumes 781-784)
• Pages: 812-817
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.781-784.812
• Online since: September 2013
• Authors: Yu Hua Gong, Xiao Jing Mu, Zhi Tao Chen, Zulipiyan Abulimite, Min Liu, Yun Yun Chen
• Keywords: Acridinium Ester, Age, Arylesterase Activity, Coronary Heart Disease

References

[1] L.G. Costa, T.B. Cole, A. Vitalone, et al: Clin. Chim. Acta 352 (2005) 37-47.

[2] M. Valiyaveettil, Y. Alamneh, P. Rezk, et al : Biochem. Pharmacol. 81 (2011) 800-809.

[3] R.J. Richter, G.P. Jarvik, and C.E. Furlong: Toxicol. Appl. Pharmacol. 235 (2009) 1-9.

[4] R.H. Coombes, J.A. Crow, M.B. Dail, et al: Pharmacogenet. Genom. 21 (2011) 867.

[5] P.N. Durrington, B. Mackness, and M.I.: Mackness: Arterioscl. Throm. Vas. Biol. 21 (2001) 473-480.

[6] H. Soran, N.N. Younis, V. Charlton-Menys, et al : Curr. Opin. Lipidol. 20 (2009) 265-274.

[7] J.A. Troughton, J.V. Woodside, J.W.G. Yarnell, et al: Atherosclerosis 197 (2008) 556-563.

[8] B. Goswami, D. Tayal, N. Gupta, et al: Clin. Chim. Acta 410 (2009) 1-9.

[9] M. Koren-Gluzer, M. Aviram, E. Meilin, et al: Atherosclerosis 219 (2011) 510-518.

DOI: 10.1016/j.atherosclerosis.2011.07.119

[10] J. Pera-Kajan, and H. Jakubowski: Amino acids 43 (2012) 1405.

[11] L.G. Costa, G. Giordano, and C.E. Furlong: Biochem. Pharmacol. 81 (2011) 337-344.

[12] X. Mu, N. Yu, C. Wang, et al: Talanta 88 (2012) 711-716.

[13] J. Camps, J. Marsillach, and J. Joven: Crit. Rev. Clin. Lab. Sci. 46 (2009), 83-106.

[14] M. Naderi, M. Hashemi, F. Komijani-Bozchaloei, et al: Pathophysiology 18 (2011) 117-120.

[15] C. Boesch-Saadatmandi, G. Rimbach, C. Schrader, et al: Mol. Nutr. Food Res. 54 (2010) 1842-1850.

DOI: 10.1002/mnfr.201000190

[16] L. Gaita, B. Manzi, R. Sacco, et al. Psychiatry Res. 180 (2010) 105-113.

[17] T. Bayrak, A. Bayrak, E. Demirpence, et al: J. Chromatogr B 878 (2010) 1791-1795.

[18] M.M. Mehdi, and S.I. Rizvi: Arch. Med. Res. 43 (2012) 438-443.